CN106581528A - Traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative - Google Patents
Traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative Download PDFInfo
- Publication number
- CN106581528A CN106581528A CN201610904034.2A CN201610904034A CN106581528A CN 106581528 A CN106581528 A CN 106581528A CN 201610904034 A CN201610904034 A CN 201610904034A CN 106581528 A CN106581528 A CN 106581528A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- rhizoma
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicine and pharmacy, and especially relates to a traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative. The traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative comprises the following components: phellodendron barks, scutellaria roots, rheum officinale, petiolate paris roots, cyrtomium rhizomes, akebia fruits, vietnamese sophora roots, smooth greenbrier roots, fiveleaf gynostemma herbs, Chinese magnoliavine fruits, Hedyotis diffusa, polyporus, ganoderma, astragali roots, Pseudostellaria heterophylla, and licorice. The medicinal materials complement each other, the formula is prepared according to a certain weight proportion based on theory of traditional Chinese medicine, and the formula has substantial curative effects for treating hepatitis B, and has efficacies for drying dampness, detoxifying, soothing liver and invigorating spleen, reinforcing the healthy qi and dispelling evils, regulating qi and resolving stasis, resisting cancer, and the like; the formula has the advantages of safety, reliability, substantial curative effects, good effects without side-effects, safety and low production cost.
Description
（One）Technical field
The present invention relates to technical field of Chinese medicine, more particularly to a kind of to treat the Chinese medicine formula that hepatitis B DNA virus is turned out cloudy.
（Two）Background technology
Hepatitis B, abbreviation hepatitis B is that one kind infects disease caused after body by hepatitis B viruss (HBV).
Hepatitis B viruss are a kind of Hepadna Virus, are primarily present in hepatocyte and damage hepatocyte, cause hepatocyte inflammation, bad
Extremely, fibrosiss.
, in worldwide prevalence, the epidemic strength of different regions HBV infection is widely different, defends according to worldwide for hepatitis B infection
Raw Organization, global about 2,000,000,000 people once infected HBV, wherein 3.5 hundred million people are chronic infection, there are about 1,000,000 people every year dead
Liver liver failure, liver cirrhosis and primary hepatocarcinoma (HCC) caused by HBV infection.The prevalence of hepatitis B that China was carried out in 2006
The survey showed that for virus, and China 1-59 crowd hepatitis B surface antigen carrying rate is 7.18%, and the HBsAg of less than 5 years old child takes
Band rate is only 0.96%, is calculated accordingly, about 93,000,000 people of the existing Patients with Chronic HBV Infection of China, wherein there is symptom to need treatment
Activeness hepatitis B patient about more than 2,000 ten thousand.Conventional Therapeutic Method is interference hormone injection and nucleoside (acid) class medicine at present
Thing, and this kind of drug side effect is big, course for the treatment of length, effect are poor, easily cause other complication, the easy drug resistance of life-time service, to trouble
Person brings spiritual and economic dual-pressure.
（Three）The content of the invention
The present invention is in order to make up the deficiencies in the prior art, there is provided a kind of to treat the Chinese medicine formula that hepatitis B DNA virus is turned out cloudy.
The present invention is achieved through the following technical solutions：
It is a kind of to treat the Chinese medicine formula that hepatitis B DNA virus is turned out cloudy, it is characterised in that：Including the raw material of following weight proportion：Radix Sophorae Flavescentiss
1-2 parts, Cortex Phellodendri 1-3 parts, Radix Scutellariae 1-3 parts, Radix Et Rhizoma Rhei 1-3 parts, Rhizoma Paridis 1-2 parts, Rhizoma Osmundae 1-2 part, Fructus Akebiae 1-3 parts, Radix Sophorae Tonkinensiss 1-
2 parts, Rhizoma Smilacis Glabrae 1-6 parts, Herb Gynostemmae Pentaphylli 1-6 parts, Fructus Schisandrae Chinensis 1-3 parts, Herba Hedyotidis Diffusae 1-10 parts, Polyporus 1-3 parts, Ganoderma 1-3
Part, Radix Astragali 1-6 parts, Radix Pseudostellariae 1-3 parts, Radix Glycyrrhizae 1-2 parts.
Further, including the raw material of following weight proportion：2 parts of Radix Sophorae Flavescentiss, 3 parts of Cortex Phellodendri, 3 parts of Radix Scutellariae, 3 parts of Radix Et Rhizoma Rhei, Rhizoma Paridis 2
Part, 2 parts of Rhizoma Osmundae, 3 parts of Fructus Akebiae, 2 parts of Radix Sophorae Tonkinensiss, 6 parts of Rhizoma Smilacis Glabrae, 6 parts of Herb Gynostemmae Pentaphylli, 3 parts of Fructus Schisandrae Chinensis, 10 parts of Herba Hedyotidis Diffusae,
3 parts of Polyporus, 3 parts of Ganoderma, 5 parts of the Radix Astragali, 3 parts of Radix Pseudostellariae, 1.5 parts of Radix Glycyrrhizae.
Wherein, the Chinese medicine is decoction, by decoction being taken warmly after above-mentioned composition by weight Chinese medicine decocting, daily one, the morning and evening each one
Secondary, every three months is a course for the treatment of, and child takes the circumstances into consideration decrement.
The following is effect of raw material of the present invention：
Radix Sophorae Flavescentiss：【Effect】Heat clearing and damp drying, dispelling wind for relieving itching；Clearing away heat and promoting diuresiss, discharging fresh blood stool, jaundice, dysuria, edema, leukorrhagia are cloudy
Itch, scabies, leprosy, skin pruritus, noxious dampness skin infection；
【Pharmacology】Diuresis, antitumor action.
Cortex Phellodendri：【Effect】Eliminating fire and detoxication, heat clearing and damp drying, consolidating YIN pathogenic fire purging；
【Pharmacology】Blood pressure lowering, blood sugar lowering, function of gallbladder promoting, stomach invigorating, anti-inflammation etc..
Radix Scutellariae：【Effect】Clearing away heat-fire, dampness removing toxic substances, hemostasis are antiabortive；
【Pharmacology】Antipyretic, antiallergic, calmness, blood pressure lowering, diuresis, hepatoprotective, anticancer etc. are acted on.
Radix Et Rhizoma Rhei：【Effect】Capture pathogenic fire purging, heat clearing and damp drying, removing heat from blood clots absorbing, heat-clearing and toxic substances removing etc.；
【Pharmacology】Discharge function, diuresis, choleretic effect, antitumaous effect, anastalsis etc..
Rhizoma Paridis【Effect】：Heat-clearing and toxic substances removing, dispelling wind and relieving convulsion, anticancer etc..
Rhizoma Osmundae：【Effect】Heat-clearing and toxic substances removing, parasite killing；
【Pharmacology】Antiviral, antibacterial, antitumor etc. are acted on.
Fructus Akebiae：【Effect】Depressed liver-energy dispersing and QI regulating, for costa sternaless pain, stagnation of liver-QI and stomach-QI, painful and swollen testis, scrofula, breast carcinoma and disappear
Change system cancerous protuberance.
Radix Sophorae Tonkinensiss：【Effect】Heat-clearing and toxic substances removing, detumescence sore-throat relieving；
【Pharmacology】Leukocyte increasing, antitumor, antiinflammatory liver protection etc. are acted on.
Rhizoma Smilacis Glabrae：【Effect】Clearing heat, detoxicating, dispelling dampness.
Herb Gynostemmae Pentaphylli：【Effect】Replenishing QI to invigorate the spleen, preventing phlegm from forming and stopping coughing, heat-clearing and toxic substances removing；
【Pharmacology】Antioxidation, high temperature resistance, antitumor, liver protection, enhancing nonspecific immunity, cellular immunization and humoral immunization, raising SOD
Activity.
Fructus Schisandrae Chinensis：【Effect】Astringing lung-QI and relieving cough, relieving diarrhea with astringents, promote the production of body fluid arresting sweating；
【Pharmacology】The third enzyme effect of paddy, drops in liver protection effect.
Herba Hedyotidis Diffusae：【Effect】Heat-clearing and toxic substances removing, eliminating damp-heat, anticancer；
【Pharmacology】Antitumor action, enhancing human body immunity ability, enhancing adrenal gland's sebum function etc..
Polyporus：【Effect】Eliminating dampness and diuresises；
【Pharmacology】Diuresis, antitumor action, antibacterial action etc..
Ganoderma：【Effect】Invigorating the spleen and replenishing QI, tranquillizing and allaying excitement, relieving cough and asthma；
【Pharmacology】Liver protection effect, mitigation hepatic necrosis, promote liver cell regeneration, reduce transaminase, improve reticuloendothelial system
Phagocytic function.
The Radix Astragali：【Effect】Tonifying Qi and lifting yang, strengthening superficial resistance to stop perspiration, inducing diuresis to remove edema, blood-nourishing of promoting the production of body fluid, the stagnant logical spleen of row, expelling pus and toxin by strengthening QI, hold back
Skin ulcer life；
【Pharmacology】Enhancing immunity, antitumor and liver protection etc. are acted on.
Radix Pseudostellariae：【Effect】Replenishing QI to invigorate the spleen, promoting the production of body fluid for nourishing the lung；
【Pharmacology】Strengthen immunity.
Radix Glycyrrhizae：【Effect】Invigorating the spleen and replenishing QI, eliminating fire and detoxication, relieving spasm to stop pain, mediation property of medicine, nourishing the lung to arrest cough；
【Pharmacology】Detoxication, adrenocortical hormone effect, eliminating phlegm and relieving cough, antiulcer, spasmolytic, anticancer etc. are acted on.
The application Chinese medicine has antitumaous effect, improves the phagocytic activity of leukocyte and reticuloendothelial cell, strengthens peripheral blood
Lymphocyte NK active functions, the function such as enhancing human body immunity function and promotion antibody formation；By clinical observation, can be effectively
Suppress hepatitis B DNA virus replication, kill and remove hepatitis B DNA virus, it is liver cirrhosis and hepatocarcinoma to block hepatitis B DNA viral progression
Intermediate link.
The traditional Chinese medical science thinks that the touching difficulty of hepatitis B heals, and its Anttdisease Mechanism accumulates deeply for evil poison, remaining evil unclear, healthy energy consume, disorder of QI and blood.Its
Etiological is epidemic disease caused by damp-heat pathogen poison, invades liver, causes spleen insufficiency, positive QI-insufficiency, virus delay to become chronic viral hepatitis B virus and take
Carrier state causes morbidity.
The application is normal to 136 hepatic and renal functions and routine blood test, and HBV-DNA virus-positives patient carries out half a year by a definite date
Clinical treatment observation, looks into HBV-DNA fluorescent quantitations less than 5.00E+02copies/mL ~ 1.0* using PCR methods before and after treatment
103Copies/mL is to turn out cloudy（Reference value<1.0*103copies/mL）, it is significantly reduced to before the relatively treatment of HBV-DNA fluorescent quantitations
Effectively.Its result HBV-DNA negative conversion rate 95.59%（130/136）, effective percentage 4.41%（6/136）, total effective rate 100% is invalid
Rate is zero；Wherein e antigen positives person 82, e antigens turn out cloudy 78, e antigens negative conversion rate 95.12%（78/82）,（4 e antigens sun
Property person is because of financial difficulties midway abandoning cure）, hepatitis b surface antigen positive person 136, anti-hepatitis B surface antigen 1, hepatitis B
Surface antigen negative conversion rate 0.73%（1/136）；HBV-DNA virus Resistance mutation bounce-back cases are had no in the course for the treatment of.
The invention has the beneficial effects as follows：The medical material that the present invention is adopted complements each other, according to theory of Chinese medical science prescription, according to certain
Weight proportion be formulated for treatment hepatitis B have significant curative effect, with dampness detoxify, soothing liver and strengthening spleen, strengthening vital QI to eliminate pathogenic factors, reason
The effects such as gasification stasis of blood, anticancer, and which is safe and reliable, and evident in efficacy, effect is good, safety, has no side effect, low production cost.
（Four）Specific embodiment
Embodiment 1：
1 part of Radix Sophorae Flavescentiss, 1 part of Cortex Phellodendri, 1 part of Radix Scutellariae, 1 part of Radix Et Rhizoma Rhei, 1 part of Rhizoma Paridis, 1 part of Rhizoma Osmundae, 1 part of Fructus Akebiae, 1 part of Radix Sophorae Tonkinensiss, Rhizoma Smilacis Glabrae
1 part of Siberian cocklebur, 1 part of Herb Gynostemmae Pentaphylli, 1 part of Fructus Schisandrae Chinensis, 1 part of Herba Hedyotidis Diffusae, 1 part of Polyporus, 1 part of Ganoderma, 1 part of the Radix Astragali, 1 part of Radix Pseudostellariae are sweet
1 part of grass.
Embodiment 2：
2 parts of Radix Sophorae Flavescentiss, 3 parts of Cortex Phellodendri, 3 parts of Radix Scutellariae, 3 parts of Radix Et Rhizoma Rhei, 2 parts of Rhizoma Paridis, 2 parts of Rhizoma Osmundae, 3 parts of Fructus Akebiae, 2 parts of Radix Sophorae Tonkinensiss, Rhizoma Smilacis Glabrae
6 parts of Siberian cocklebur, 6 parts of Herb Gynostemmae Pentaphylli, 3 parts of Fructus Schisandrae Chinensis, 10 parts of Herba Hedyotidis Diffusae, 3 parts of Polyporus, 3 parts of Ganoderma, 6 parts of the Radix Astragali, 3 parts of Radix Pseudostellariae,
2 parts of Radix Glycyrrhizae.
Embodiment 3：
2 parts of Radix Sophorae Flavescentiss, 3 parts of Cortex Phellodendri, 3 parts of Radix Scutellariae, 3 parts of Radix Et Rhizoma Rhei, 2 parts of Rhizoma Paridis, 2 parts of Rhizoma Osmundae, 3 parts of Fructus Akebiae, 2 parts of Radix Sophorae Tonkinensiss, Rhizoma Smilacis Glabrae
6 parts of Siberian cocklebur, 6 parts of Herb Gynostemmae Pentaphylli, 3 parts of Fructus Schisandrae Chinensis, 10 parts of Herba Hedyotidis Diffusae, 3 parts of Polyporus, 3 parts of Ganoderma, 5 parts of the Radix Astragali, 3 parts of Radix Pseudostellariae,
1.5 parts of Radix Glycyrrhizae.
Embodiment 4
Model case：
Case 1：
Patient Liu, man 38 years old, businessman, Henan Zhumadian people have found that hepatitis B small three positive virus is carried more than 10 years, by wide before treatment
State health all Clinical Laboratorys adopt PCR methods to look into HBV-DNA fluorescent quantitations for 2.77*104copies/mL（Reference value is less than 1.0*
103copies/mL ）Jing treats a course for the treatment of to Peng Buming hepatitis B detoxification soups, by the checked HBV- of Guangzhou health all Clinical Laboratorys
DNA fluorescent quantitation results are turned out cloudy, and hepatic and renal function and routine blood test are normal.
Case 2：
Patient Lee, man 30 years old, businessman, Sichuan Shou Renxian people have found hepatitis B small three positive more than the 3 years carrying time of virus.Before treatment
It is 2.4*10 by the adopted PCR methods HBV-DNA fluorescent quantitation of Guangzhou health all Clinical Laboratorys6Copies/mL, Jing give Peng Buming hepatitis B
1 course for the treatment of of Detoxication Decoction, is turned out cloudy by the checked HBV-DNA fluorescent quantitations result of Guangzhou health all Clinical Laboratorys, and hepatic and renal function and blood are normal
Rule are normal
Case 3：
Patient Lee, man 31 years old, people from Fusui County have found hepatitis B virus small three positive more than the 6 years carrying time of virus.Treatment before by
Guangzhou gold domain clinical medicine inspection center adopts PCR methods to look into HBV-DNA fluorescent quantitations for 4.74E+05copies/mL（Reference value
Less than 5.00E+02copies/mL）Jing is treated 2 months to Peng Buming hepatitis B detoxification soups, by the clinical medicine inspection of Guangzhou gold domain
Heart check HBV-DNA fluorescent quantitation results are turned out cloudy, and hepatic and renal function and routine blood test are normal.
Case 4：
Patient poplar, man 21 years old, find hepatitis B great three positive more than the 3 years carrying time of virus, by all Clinical Laboratorys of Guangzhou health before treatment
Institute looks into HBV-DNA fluorescent quantitation 2.79*10 using PCR methods8Copies/mL, it is clinical up to peace by Guangzhou Zhongshan University after 1 course for the treatment of
Inspection center check HBV-DNA fluorescent quantitation results are turned out cloudy, and hepatic and renal function and routine blood test are normal；
Case 5：
Patient Lee, man 25 years old, have found hepatitis B great three positive more than the 5 years carrying time of virus, by the Clinical Laboratorys of Guangzhou health before treatment
The PCR methods that adopt look into HBV-DNA fluorescent quantitations for 1.48*108Copies/mL, Jing treat 2 treatments to Peng Buming hepatitis B detoxification soups
Journey is turned out cloudy by the checked HBV-DNA fluorescent quantitations result of Guangzhou health all Clinical Laboratorys, and hepatic and renal function and routine blood test are normal.
Claims (3)
- It is 1. a kind of to treat the Chinese medicine formula that hepatitis B DNA virus is turned out cloudy, it is characterised in that：Including the raw material of following weight proportion：It is bitter Ginseng 1-2 parts, Cortex Phellodendri 1-3 parts, Radix Scutellariae 1-3 parts, Radix Et Rhizoma Rhei 1-3 parts, Rhizoma Paridis 1-2 parts, Rhizoma Osmundae 1-2 part, Fructus Akebiae 1-3 parts, Radix Sophorae Tonkinensiss 1-2 parts, Rhizoma Smilacis Glabrae 1-6 parts, Herb Gynostemmae Pentaphylli 1-6 parts, Fructus Schisandrae Chinensis 1-3 parts, Herba Hedyotidis Diffusae 1-10 parts, Polyporus 1-3 parts, Ganoderma 1-3 Part, Radix Astragali 1-6 parts, Radix Pseudostellariae 1-3 parts, Radix Glycyrrhizae 1-2 parts.
- 2. the Chinese medicine formula that treatment hepatitis B DNA virus according to claim 1 is turned out cloudy, it is characterised in that：Including following heavy The raw material of amount proportioning：2 parts of Radix Sophorae Flavescentiss, 3 parts of Cortex Phellodendri, 3 parts of Radix Scutellariae, 3 parts of Radix Et Rhizoma Rhei, 2 parts of Rhizoma Paridis, 2 parts of Rhizoma Osmundae, 3 parts of Fructus Akebiae, mountain bean 2 parts of root, 6 parts of Rhizoma Smilacis Glabrae, 6 parts of Herb Gynostemmae Pentaphylli, 3 parts of Fructus Schisandrae Chinensis, 10 parts of Herba Hedyotidis Diffusae, 3 parts of Polyporus, 3 parts of Ganoderma, 5 parts of the Radix Astragali, 3 parts of Radix Pseudostellariae, 1.5 parts of Radix Glycyrrhizae.
- 3. the Chinese medicine formula that treatment hepatitis B DNA virus according to claim 1 and 2 is turned out cloudy, it is characterised in that：The Chinese medicine For decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610904034.2A CN106581528A (en) | 2016-10-18 | 2016-10-18 | Traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610904034.2A CN106581528A (en) | 2016-10-18 | 2016-10-18 | Traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581528A true CN106581528A (en) | 2017-04-26 |
Family
ID=58555557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610904034.2A Pending CN106581528A (en) | 2016-10-18 | 2016-10-18 | Traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581528A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296831A (en) * | 2000-11-27 | 2001-05-30 | 刘济铭 | Capsule for converting to negative for hepatitis B and its preparing process |
| CN103920074A (en) * | 2014-04-25 | 2014-07-16 | 解建峰 | Traditional Chinese medicine composition for treating hepatitis B |
-
2016
- 2016-10-18 CN CN201610904034.2A patent/CN106581528A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296831A (en) * | 2000-11-27 | 2001-05-30 | 刘济铭 | Capsule for converting to negative for hepatitis B and its preparing process |
| CN103920074A (en) * | 2014-04-25 | 2014-07-16 | 解建峰 | Traditional Chinese medicine composition for treating hepatitis B |
Non-Patent Citations (2)
| Title |
|---|
| 彭布明: "中西药物结合治疗乙肝DNA病毒阳性100例疗效观察", 《2012年广东省肝脏病学会中医药学专业委员会学术会议论文汇编》 * |
| 彭布明: "乙肝解毒汤治疗乙肝DNA病毒阳性7例疗效观察", 《中外医疗》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101637585B (en) | Chinese herbal preparation for treating posirasis and preparation method thereof | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN103083582B (en) | Medicine for treating hyperlipidemia | |
| CN101028450A (en) | Medicinal composition for treating cardica cerebrovascular diseases | |
| CN1112201C (en) | Chinese medicine for curing hepatitis B and cirrhosis ascites | |
| CN102973862A (en) | Chinese medicine preparation for treating skin itch | |
| CN103142920B (en) | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof | |
| CN102552512B (en) | Traditional Chinese medicine used for treating hepatitis B | |
| CN101912524B (en) | Schisandra liver-benefiting capsules | |
| CN102198234A (en) | Chinese herbal medicine preparation for treating acute viral myocarditis accompanied by bowel sepsis | |
| CN104606514A (en) | Traditional Chinese medicine composition for treating kidney deficiency type tinnitus | |
| CN104147526A (en) | Traditional Chinese medicine particles for treating icteric hepatitis and preparation method thereof | |
| CN106581528A (en) | Traditional Chinese medicine formula for treating hepatitis B and converting DNA virus into negative | |
| CN103550681B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B | |
| CN102240342A (en) | Traditional Chinese medicine for treating viral hepatitis A | |
| CN102406906A (en) | Traditional Chinese medicine composition for treating acute hepatitis B | |
| CN100518800C (en) | Medicinal composition for treating hepatitis B | |
| CN103656314A (en) | Traditional Chinese medicinal preparation for treating hepatitis A | |
| CN102772595B (en) | Traditional Chinese composition for treating chronic hepatitis B | |
| CN1162163C (en) | Chinese herbal medicinal liquor for curing rheumatic arthritis | |
| CN1876062A (en) | Preparation method of traditional Chinese medicine for treating hepatitis B and liver cirrhosis and Chinese medicine prepared thereby | |
| CN111888418A (en) | Chinese medicinal composition for preventing and treating hepatitis and preparation method thereof | |
| CN105477454A (en) | Traditional Chinese medicine composition for treating eczema | |
| CN104524054A (en) | Traditional Chinese medicinal enema for treating viral hepatitis A | |
| CN111228388A (en) | A pharmaceutical composition for treating hepatopathy, and its application method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |